Mumbai, India, August 09, 2011: Cancer Trials Australia (CTA) announced that it has entered into a collaboration agreement with Mumbai based Clininvent Research Private Limited (CRPL) with the aim to leverage complimentary capabilities in selected areas of clinical development and offer services spanning phases I to IV, to clients in Australia and India.
The combination of CTA’s experience in Phase 1 clinical trials, which has led the company to become a major centre for such studies in Australia, and Clininvent’s proven tracked record of managing multisite trials, recruiting patient in large numbers, optimum GCP and protocol design compliance, will ensure scale and competitive advantage for both partners.
Mr Marcus Clark, CEO of CTA said; “We expect that this collaboration will be highly advantageous to our clients as it allows for a seamless transition from a phase I centre to a network that includes sites in both India and Australia. With both CTA and Clininvent collaborating to offer trial design, ethics and governance management, site initiation and monitoring there will be significant efficiencies achieved for client companies.”
“We are very pleased to partner with CTA, a prestigious Australian cancer clinical trials organisation. Our experience of managing late phase oncology trials will enable this collaboration to provide clients with reduction in lead times for approvals and start ups, while continuing to ensure high and timely level of recruitment,” said Dr Bhatt, President, Clininvent.
Clininvent Research Private Limited (CRPL) based in Mumbai is a subsidiary of TCG Lifesciences Limited, a leading global integrated drug discovery and development research Services Company, a part of The Chatterjee Group (TCG) headquartered in New York. Clininvent offers a suite of high quality, cost effective and user friendly clinical research services to the pharmaceutical, biotechnology and medical industries.
CTA is a Melbourne-based not-for-profit service organisation that conducts cancer clinical trials on behalf of investigators and sponsors, namely biotechnology and pharmaceutical companies. As a member-based organisation comprising research institutes and hospitals, CTA has access to a diverse range of expertise and technology.
For further information please contact:
CTA
Mr. Marcus Clark, Chief Executive Officer: Ph: 61 3 9342 7306 or email - m.clark@cancertrialsaustralia.com
Clininvent Research Private Limited, India
Dr Arun Bhatt, President – Clinical Development, Ph: 91-33-2367 3151 or email - arunbhatt@clininvent.com
Clininvent, Mantrax Ventures representing Clininvent in Australia
Ms. Julia Hill, Director: Ph: 61 3 8685 8934 or
email - hill@mantraxventures.com
